Breakthrough Treatment for PBC Patients' 'Relentless Itch' Nears EU Approval
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
GSK announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application for linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC).
Key highlights:
- The application is based on positive results from the GLISTEN phase III trial, which met both primary and secondary endpoints
- Linerixibat demonstrated rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo
- The drug addresses an unmet medical need, as up to 90% of PBC patients experience pruritus, with current first-line treatments not reducing its severity
- The trial involved 238 PBC patients across 19 countries, marking it as the first truly global PBC study
This EMA acceptance follows FDA acceptance earlier in the month. Linerixibat has received orphan drug designation from both FDA and EMA, and is currently under review in the US and UK markets.
Positive
- EMA accepted linerixibat for review to treat cholestatic pruritus in PBC patients, following recent FDA acceptance - expanding potential market access for this orphan drug
- Phase III GLISTEN trial demonstrated rapid, significant and sustained improvement in both primary and key secondary endpoints for cholestatic pruritus treatment
- Drug addresses high unmet medical need with 90% of PBC patients experiencing pruritus and limited effective treatment options currently available
- Global market potential demonstrated through trial conducted across 19 countries including major markets (Americas, Europe, China, and Japan)
Negative
- Linerixibat is not yet approved in any market, indicating revenue generation is still contingent on regulatory approvals
- Competition from existing first-line PBC treatments which control disease in approximately 70% of patients, though they don't address pruritus specifically
FAQ
What is GSK's linerixibat drug candidate and what was announced in June 2025?
GSK announced that the European Medicines Agency (EMA) accepted for review the marketing authorisation application for linerixibat, an investigational ileal bile acid transporter (IBAT) inhibitor. The drug is being developed to treat cholestatic pruritus in patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease.
What were the results of GSK's GLISTEN Phase III trial for linerixibat?
The GLISTEN Phase III trial met both primary and key secondary endpoints, demonstrating rapid, significant and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo. The trial involved 238 PBC patients and was conducted across 19 countries including the Americas, Europe, China and Japan.
What is the market opportunity for GSK's linerixibat in PBC patients?
According to the filing, up to 90% of people living with PBC experience cholestatic pruritus (relentless itch) in varying degrees of severity. The current first-line treatment for PBC controls disease in approximately 70% of patients but does not reduce the severity or impact of the pruritus, representing a significant unmet medical need.
What is the current regulatory status of GSK's linerixibat?
As of June 2025, linerixibat is under regulatory review by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). The drug has received orphan drug designation from both agencies for treating cholestatic pruritus in PBC patients. It is also under review in the UK but is not yet approved anywhere in the world.
What other liver diseases is GSK currently researching besides PBC?
GSK disclosed that beyond PBC, they are investigating potential treatments for chronic hepatitis B, alcohol-related liver disease (ALD), and metabolic dysfunction-associated steatohepatitis (MASH) as part of their hepatology research portfolio.